Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Sirion Therapeutics (Zirgan)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Assets and U.S. rights for Zirgan. It is a topical anti-viral for the treatment of corneal ulcers. It conveys special status for rare diseases or conditions that affect fewer than 200,000 patients in the U.S.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Commercial Services
Acquirer
Primary Office
  • 3110 Cherry Palm Drive
  • Suite 340
  • Tampa, FL 33619
  • United States

Sirion Therapeutics (Zirgan) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Sirion Therapeutics (Zirgan)‘s full profile, request access.

Request full access to PitchBook

Sirion Therapeutics (Zirgan) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Sirion Therapeutics (Zirgan)‘s full profile, request access.

Request full access to PitchBook